Abstract
Emily Alouani, Jean-David Fumet, Paul Johannet, Aurélien Marabelle, Benoit Rousseau
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
10.1126/science.aaa1348 · 2015
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
10.1126/science.aan6733 · 2017
Genomic correlates of response to immune checkpoint blockade
10.1038/s41591-019-0382-x · 2019
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
10.1126/science.aaf8399 · 2017
TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes
10.1073/pnas.1500973112 · 2015
Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade
10.1016/j.cels.2019.08.009 · 2019
Genetic basis for clinical response to CTLA-4 blockade in melanoma
10.1056/nejmoa1406498 · 2014
Therapeutic targeting of mismatch repair-deficient cancers
10.1038/s41571-025-01054-6 · 2025
Neoantigens in cancer immunotherapy
10.1126/science.aaa4971 · 2015
Confidence 0%
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
10.1038/s41416-018-0220-9 · 2018
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
10.1038/nature24673 · 2017
Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
10.1126/science.aau0447 · 2019
PD-1 blockade in solid tumors with defects in polymerase epsilon
10.1158/2159-8290.cd-21-0521 · 2022
Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
10.1038/s41588-022-01108-w · 2022
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
10.1016/j.annonc.2024.03.009 · 2024
DNA polymerase and mismatch repair exert distinct microsatellite instability signatures in normal and malignant human cells
10.1158/2159-8290.cd-20-0790 · 2021
Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers
10.1136/gutjnl-2019-320462 · 2021
Pan-cancer interrogation of MUTYH variants reveals biallelic inactivation and defective base excision repair across a spectrum of solid tumors
10.1200/po.23.00251 · 2024
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer
10.1007/s10637-019-00842-z · 2020
Germline MBD4 deficiency causes a multi-tumor predisposition syndrome
10.1016/j.ajhg.2022.03.018 · 2022
Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors
10.1038/s41467-018-04322-5 · 2018
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients
10.1016/j.ejca.2022.06.033 · 2022
Positive association between location of melanoma, ultraviolet signature, tumor mutational burden, and response to anti-PD-1 therapy
2021
Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
10.1002/1878-0261.12748 · 2020
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
10.1016/j.cell.2021.01.002 · 2021
The immune landscape of cancer
10.1016/j.immuni.2018.03.023 · 2018
On the origin of G T transversions in lung cancer
2003
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
10.21037/tlcr-20-559 · 2021
Mutational signatures of ionizing radiation in second malignancies
10.1038/ncomms12605 · 2016
Emerging evidence for adapting radiotherapy to immunotherapy
10.1038/s41571-023-00782-x · 2023
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
10.1038/ncomms15618 · 2017
The mutational footprints of cancer therapies
10.1038/s41588-019-0525-5 · 2019
Genomic, pathway network, and immunologic features distinguishing squamous carcinomas
10.1016/j.celrep.2018.03.063 · 2018
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
10.1038/s41467-017-02320-7 · 2017
Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial
10.1200/jco.21.02583 · 2022
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients
10.1158/2159-8290.cd-21-1434 · 2022
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer
10.1016/j.ccell.2025.05.010 · 2025
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models
10.1016/j.ccell.2025.05.014 · 2025
Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancer
10.1158/1078-0432.ccr-25-2566 · 2026
Mechanisms and therapeutic implications of hypermutation in gliomas
10.1038/s41586-020-2209-9 · 2020
Pan-cancer landscape of homologous recombination deficiency
10.1038/s41467-020-19406-4 · doi-reference
Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures
10.1038/s41467-022-30916-1 · doi-reference
MBD4-associated neoplasia syndrome: screening of cases with suggestive phenotypes
10.1038/s41431-023-01418-5 · doi-reference
Tumor mutational burden and response rate to PD-1 inhibition
10.1056/nejmc1713444 · doi-reference
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
10.1038/s41587-021-01070-8 · doi-reference
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
10.1038/s41591-020-0856-x · doi-reference
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
10.1016/j.xcrm.2022.100878 · doi-reference
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
10.1136/jitc-2020-000842 · doi-reference
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy
10.1016/j.ejca.2022.08.034 · doi-reference
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients
10.1126/science.adf1329 · doi-reference
Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade
10.1158/2159-8290.cd-20-0812 · doi-reference
TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes antitumor immunity
10.1158/2159-8290.cd-23-0700 · doi-reference
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
10.1016/j.ccell.2021.06.018 · doi-reference
Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small-molecule reactivator
10.1158/2159-8290.cd-24-1421 · doi-reference
Rezatapopt (PC14586): a first-in-class small molecule p53 Y220C mutant protein stabilizer in clinical trials
10.1021/acs.jmedchem.5c00670 · doi-reference
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
10.1038/s41591-025-03575-0 · doi-reference
Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma
10.1200/jco.20.03167 · doi-reference
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia
10.3324/haematol.2023.283510 · doi-reference
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers
10.1038/s43018-023-00699-5 · doi-reference
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
10.1038/s41591-024-02808-y · doi-reference
ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer
10.1126/sciadv.ado4618 · doi-reference
Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
10.1001/jamaoncol.2019.1048 · doi-reference
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
10.1001/jamaoncol.2019.1029 · doi-reference
Abstract CT004: KEYLYNK-007: tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers
10.1158/1538-7445.am2025-ct004 · doi-reference
814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
10.1016/j.annonc.2020.08.953 · doi-reference
PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness
10.1158/0008-5472.can-18-1003 · doi-reference
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
10.1093/annonc/mdz135 · doi-reference
479MO Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
10.1016/j.annonc.2025.05.496 · doi-reference
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
10.1016/j.ejca.2025.115547 · doi-reference
Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma
10.1056/nejmoa2407417 · doi-reference
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
10.1016/s0140-6736(19)32591-7 · doi-reference
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
10.1093/annonc/mdz127 · doi-reference
Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50
10.1200/jco.21.00174 · doi-reference
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study
10.1007/s00262-020-02688-4 · doi-reference
Dostarlimab for primary advanced or recurrent endometrial cancer
10.1056/nejmoa2216334 · doi-reference
Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies
10.1136/jitc-2024-011177 · doi-reference
A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I/IIa clinical trial
10.1158/1078-0432.ccr-19-3517 · doi-reference
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
10.1136/jitc-2023-008689 · doi-reference
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
10.1016/s0140-6736(24)02848-4 · doi-reference
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
10.1038/s41591-020-0805-8 · doi-reference